Presented by: Momen M. Wahidi, MD, FCCP and W. Dean Wallace, MD Biomarker-driven targeted therapy of patients with NSCLC requires accurate diagnosis and staging. The pulmonary care team must acquire adequate biopsy tissue to enable histology, immunofluorescence and molecular biomarker testing. Presented in Los Angeles, California - October 2016.